Nicholas C. Ling

Q: What Schools Are Affiliated With Nicholas C. Ling

Nicholas C. Ling is affiliated with the following schools: Weizmann Institute of Science, University of Minnesota, Pennsylvania State University

Nicholas C. Ling's AcademicInfluence.com Rankings

Nicholas C. Ling

Philosophy

#2908

World Rank

#4822

Historical Rank

Logic

#847

World Rank

#1400

Historical Rank

philosophy Degrees

Nicholas C. Ling

Biology

#3465

World Rank

#5297

Historical Rank

Endocrinology

#13

World Rank

#16

Historical Rank

Biochemistry

#326

World Rank

#396

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Nicholas C. Ling's Degrees

PhD Biochemistry Stanford University
Doctorate Medicine Stanford University

Why Is Nicholas C. Ling Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nicholas C. Ling's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone (1973) (3343)
beta-Endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland. (1977) (1323)
Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. (1982) (1226)
Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin (1986) (1072)
Common precursor to corticotropins and endorphins. (1977) (1008)
Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. (1976) (800)
Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-β (1985) (705)
Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). (1991) (687)
Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. (1985) (647)
Neurons containing beta-endorphin in rat brain exist separately from those containing enkephalin: immunocytochemical studies. (1978) (618)
The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. (1984) (560)
Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane (1984) (534)
Foot-shock induced stress increases β-endorphin levels in blood but not brain (1977) (534)
β-ENDORPHIN AND ADRENOCORTICOTROPIN ARE SECRETED CONCOMITANTLY BY THE PITUITARY GLAND (1978) (482)
Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. (1987) (431)
Isolation and partial characterization of a Mr 32,000 protein with inhibin activity from porcine follicular fluid. (1985) (427)
Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. (1987) (416)
Regional dissociation of beta-endorphin and enkephalin contents in rat brain and pituitary. (1977) (408)
Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF) (LH-hypothalamus-LRF-gas chromatography-mass spectrometry-decapeptide-Edman degradation). (1972) (406)
Stimulation in vivo of the secretion of prolactin and growth hormone by beta-endorphin. (1977) (406)
Immunohistochemical Localization of Novel CART Peptides in Rat Hypothalamus, Pituitary and Adrenal Gland (1997) (377)
Molecular characterization of fibroblast growth factor: distribution and biological activities in various tissues. (1986) (356)
Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. (1991) (316)
Neuronal actions of endorphins and enkephalins among brain regions: a comparative microiontophoretic study. (1977) (287)
Receptor- and heparin-binding domains of basic fibroblast growth factor. (1988) (282)
Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. (1984) (282)
Leucosulfakinin, a sulfated insect neuropeptide with homology to gastrin and cholecystokinin. (1986) (278)
Endorphins are located in the intermediate and anterior lobes of the pituitary gland, not in the neurohypophysis. (1977) (270)
FOLLISTATIN BINDS TO BOTH ACTIVIN AND INHIBIN THROUGH THE COMMON BETA-SUBUNIT (1991) (253)
Molecular cloning of the cDNAs encoding a novel insulin-like growth factor-binding protein from rat and human. (1990) (250)
Immunohistochemical detection of growth hormone-releasing factor in brain (1983) (242)
Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. (1993) (241)
Age-related changes in plasma growth hormone response to growth hormone-releasing factor in man. (1984) (240)
Complementary deoxyribonucleic acid (cDNA) cloning and DNA sequence analysis of rat ovarian inhibins. (1987) (240)
Primary structure of the human follistatin precursor and its genomic organization. (1988) (239)
Isolation and sequence of the vitamin K-dependent protein from human bone. Undercarboxylation of the first glutamic acid residue. (1980) (237)
Isolation and molecular cloning of insulin-like growth factor-binding protein-6. (1991) (236)
Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease (1995) (232)
Follistatin and Activin: A Potential Intrinsic Regulatory System within Diverse Tissues (1991) (230)
The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. (1986) (230)
Inhibin and beta type transforming growth factor (TGF beta) have opposite modulating effects on the follicle stimulating hormone (FSH)-induced aromatase activity of cultured rat granulosa cells. (1986) (223)
Complementary DNA cloning and sequencing of rat ovarian basic fibroblast growth factor and tissue distribution study of its mRNA. (1988) (217)
Corticotropin-releasing factor-like activity in human placental extracts. (1982) (212)
Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. (1985) (210)
Radioimmunoassays for a-endorphin and -endorphin (1977) (209)
Physiological roles of somatocrinin and somatostatin in the regulation of growth hormone secretion. (1982) (209)
Primary structure of bovine brain acidic fibroblast growth factor (FGF). (1985) (208)
Multiple influences of a heparin-binding growth factor on neuronal development (1987) (202)
Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion (1981) (200)
Isolation and partial molecular characterization of pituitary fibroblast growth factor. (1984) (192)
Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-1-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. (1994) (189)
Pro-adrenocorticotropin/endorphin-derived peptides: coordinate action on adrenal steroidogenesis. (1980) (189)
beta-Lipotropin as a prohormone for the morphinomimetic peptides endorphins and enkephalins. (1976) (188)
Isolation, primary structure, and synthesis of α-endorphin and γ-endorphin, two peptides of hypothalamic-hypophysial origin with morphinomimetic activity (1976) (188)
The use of mass spectrometry in deducing the sequence of somatostatin--a hypothalamic polypeptide that inhibits the secretion of growth hormone. (1973) (187)
Follistatin gene expression in the ovary and extragonadal tissues. (1989) (187)
beta-Endorphin induces nonconvulsive limbic seizures. (1978) (181)
The effect of free fatty acids on growth hormone (GH)-releasing hormone-mediated GH secretion in man. (1985) (179)
Locomotor activation induced by infusion of endorphins into the ventral tegmental area: evidence for opiate-dopamine interactions. (1980) (178)
Leucosulfakinin-II, a blocked sulfated insect neuropeptide with homology to cholecystokinin and gastrin. (1986) (175)
Quantitation of rat tissue thyroid hormone binding receptor isoforms by immunoprecipitation of nuclear triiodothyronine binding capacity. (1992) (175)
Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. (1973) (174)
Primary structure of ovine hypothalamic somatostatin-28 and somatostatin-25. (1980) (172)
Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. (1987) (171)
Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. (1982) (169)
A homodimer of the β-subunits of inhibin a stimulates the secretion of pituitary follicle stimulating hormone (1986) (168)
Recombinant expression of human follistatin with 315 and 288 amino acids: chemical and biological comparison with native porcine follistatin. (1991) (167)
Biologic and immunologic activities and applications of somatostatin analogs. (1978) (166)
An insulin-like growth factor-binding protein in ovarian follicular fluid blocks follicle-stimulating hormone-stimulated steroid production by ovarian granulosa cells. (1989) (165)
Insulin-like growth factor-binding protein (IGF-BP) inhibition of granulosa cell function: effect on cyclic adenosine 3',5'-monophosphate, deoxyribonucleic acid synthesis, and comparison with the effect of an IGF-I antibody. (1990) (164)
Development of specific antibodies to rat insulin-like growth factor-binding proteins (IGFBP-2 to -6): analysis of IGFBP production by rat granulosa cells. (1993) (162)
Anatomic and phylogenetic distribution of somatostatin. (1976) (157)
Immunohistochemical distribution of pro-somatostatin-related peptides in hippocampus (1982) (156)
Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. (2000) (154)
Differential distribution of urocortin- and corticotropin-releasing factor-like immunoreactivities in the rat brain (1999) (153)
Primary structure of PDC-109, a major protein constituent of bovine seminal plasma. (1983) (150)
Cloning and sequence analysis of cDNA for the precursor of human growth hormone-releasing factor, somatocrinin. (1983) (149)
Met-enkephalin-Arg6-Phe7, present in high amounts in brain of rat, cattle and man, is an opioid agonist (1980) (149)
Somatocrinin (growth hormone releasing factor) in vitro bioactivity; Ca++ involvement, cAMP mediated action and additivity of effect with PGE2. (1982) (148)
Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. (2002) (148)
PROFOUND ANALGESIC EFFECTS OF β-ENDORPHIN IN MAN (1980) (146)
Specific depletion of immunoreactive growth hormone-releasing factor by monosodium glutamate in rat median eminence (1984) (141)
Radioimmunoassay of brain peptides: evaluation of a methodology for the assay of beta-endorphin and enkephalin. (1977) (137)
Complementary DNA structure of the high molecular weight rat insulin-like growth factor binding protein (IGF-BP3) and tissue distribution of its mRNA. (1989) (135)
Expression and characterization of a putative high affinity human soluble leptin receptor. (1997) (135)
Tissue-specific expression of four insulin-like growth factor-binding proteins (1, 2, 3, and 4) in the rat ovary. (1991) (135)
A nonmitogenic pituitary function of fibroblast growth factor: regulation of thyrotropin and prolactin secretion. (1985) (134)
Seven peptides derived from pro-somatostatin in rat brain. (1982) (133)
β-ENDORPHIN STIMULATES SECRETION OF ARGININE VASOPRESSIN IN VIVO (1977) (133)
β-Endorphin: cellular localization, electrophysiological and behavioral effects (1979) (131)
Human hypothalamic growth hormone releasing factor (GRF): evidence for two forms identical to tumor derived GRF-44-NH2 and GRF-40. (1983) (130)
Vesicular stomatitis virus glycoprotein is anchored in the viral membrane by a hydrophobic domain near the COOH terminus. (1980) (126)
Gonadocrinins: Peptides in Ovarian Follicular Fluid Stimulating the Secretion of Pituitary Gonadotropins* (1981) (126)
Porcine follistatin gene structure supports two forms of mature follistatin produced by alternative splicing. (1988) (124)
Presence of somatostatin-28-(1-12) in hypothalamus and pancreas. (1982) (122)
beta-Endorphin: endogenous opiate or neuroleptic? (1977) (122)
Somatocrinin, growth hormone releasing factor, stimulates secretion of growth hormone in anesthetized rats. (1982) (122)
Involvement of corticotropin-releasing factor in restraint stress-induced anorexia and reversion of the anorexia by somatostatin in the rat. (1988) (120)
Plasma growth hormone (GH) response to GH-releasing factor in normal children with short stature and patients with pituitary dwarfism. (1984) (115)
Characterization of an insulin-like growth factor binding protein (IGFBP-4) produced by the B104 rat neuronal cell line: chemical and biological properties and differential synthesis by sublines. (1991) (115)
Expression of inhibin beta A and beta B, follistatin and activin-A receptor messenger ribonucleic acids in the rat seminiferous epithelium. (1992) (115)
Potent interaction between glucocorticoids and growth hormone-releasing factor in vivo. (1983) (111)
High biological activity of the synthetic replicates of somatostatin-28 and somatostatin-25 (1981) (110)
Antibodies to peptide determinants in transforming growth factor beta and their applications. (1988) (110)
The effect of glucose on growth hormone (GH)-releasing hormone-mediated GH secretion in man. (1985) (109)
Growth hormone-releasing factor regulates growth hormone mRNA in primary cultures of rat pituitary cells. (1984) (109)
Type beta transforming growth factor (TGF-beta) is a potent stimulator of the basal secretion of follicle stimulating hormone (FSH) in a pituitary monolayer system. (1986) (108)
High-molecular-weight immunoreactive beta-endorphin in extracts of human placenta is a fragment of immunoglobulin G. (1980) (106)
Plasma GH responses to GHRH and insulin-induced hypoglycemia in man. (1985) (106)
Urocortin, corticotropin releasing factor-2 receptors and energy balance. (2001) (104)
Immunofluorescence localization of thyroid hormone receptor protein beta 1 and variant alpha 2 in selected tissues: cerebellar Purkinje cells as a model for beta 1 receptor-mediated developmental effects of thyroid hormone in brain. (1991) (103)
Characterization of a 40 residue peptide from a human pancreatic tumor with growth hormone releasing activity. (1982) (103)
A surface component on GH3 pituitary cells that recognizes transforming growth factor-beta, activin, and inhibin. (1988) (103)
Distribution of growth hormone-releasing hormone-like immunoreactivity in human tissue extracts. (1984) (102)
Isolation and characterization of the porcine hypothalamic growth hormone releasing factor. (1983) (101)
Follistatin specifically inhibits pituitary follicle stimulating hormone release in vitro. (1987) (100)
Opioid activities of fragments of beta-endorphin and of its leucine65-analogue. Comparison of the binding properties of methionine- and leucine-enkephalin. (1979) (100)
The effects of testosterone and estrogen on the pituitary growth hormone response to growth hormone-releasing factor. (1985) (99)
Isolation and partial characterization of basic fibroblast growth factor from bovine testis (1987) (99)
Identification of soluble forms of the fibroblast growth factor receptor in blood. (1994) (98)
Isolation and characterization of the bovine hypothalamic growth hormone releasing factor. (1983) (98)
Synthesis and biological activity of four γ-melanotropin derived from the cryptic region of the adrenocorticotropin/β-lipotropin precursor (1979) (97)
Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. (1997) (96)
Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke. (1998) (95)
Comparative effects of corticotropin-releasing factor, arginine vasopressin, and related neuropeptides on the secretion of ACTH and alpha-MSH by frog anterior pituitary cells and neurointermediate lobes in vitro. (1986) (95)
Immunohistochemical localization and radioimmunoassay of corticotropin-releasing factor in the forebrain and hypophysis of the frog Rana ridibunda. (1985) (95)
The effect of glucose and free fatty acids on growth hormone (GH)-releasing factor-mediated GH secretion in rats. (1986) (95)
Immunohistochemical detection of inhibin in the gonad. (1987) (94)
A specific homologous radioimmunoassay for human beta-endorphin: direct measurement in biological fluids. (1980) (94)
Follistatin binds to both activin and inhibin through the common subunit. (1991) (93)
Cyclic changes in follistatin messenger ribonucleic acid and its protein in the rat ovary during the estrous cycle. (1991) (93)
125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors. (1996) (93)
Stage dependent expression of inhibin α and β-B subunits during the cycle of the rat seminiferous epithelium (1989) (89)
[Leu27] insulin-like growth factor II is highly selective for the type-II IGF receptor in binding, cross-linking and thymidine incorporation experiments. (1991) (88)
Isolation and partial characterization of an endothelial cell growth factor from the bovine kidney: homology with basic fibroblast growth factor (1985) (87)
A new prosomatostatin-derived peptide reveals a pattern for prohormone cleavage at monobasic sites. (1987) (86)
Structural characterization of a follicle-stimulating hormone action inhibitor in porcine ovarian follicular fluid. Its identification as the insulin-like growth factor-binding protein. (1990) (85)
Topographical and ontogenetic study of the neurons producing growth hormone-releasing factor in human hypothalamus (1984) (85)
Secretion of follicle-stimulating hormone and production of inhibin are reciprocally related. (1987) (84)
Injection of anti-neuropeptide Y γ-globulin into the hypothalamic paraventricular nucleus decreases food intake in rats (1993) (84)
Localization of insulin-like growth factor-binding protein-5 messenger ribonucleic acid in rat ovaries during the estrous cycle. (1992) (83)
Cyclic changes in insulin-like growth factor-binding protein-4 messenger ribonucleic acid in the rat ovary. (1992) (82)
Pituitary growth hormone response in rats during a 24-hour infusion of growth hormone-releasing factor. (1984) (80)
Sensitive colorimetric bioassays for insulin-like growth factor (IGF) stimulation of cell proliferation and glucose consumption: use in studies of IGF analogs. (1992) (77)
Solid phase synthesis of somatostatin-28. (1980) (77)
Local production and action of follistatin in human placenta. (1994) (76)
Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. (1996) (75)
Somatostatin-28 is longer acting and more selective than somatostatin-14 on pituitary and pancreatic hormone release. (1982) (72)
Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists. (2004) (70)
Decrease in beta-subunit phosphotyrosine correlates with internalization and activation of the endosomal insulin receptor kinase. (1992) (70)
In vitro release of growth hormone-releasing factor from rat hypothalamus: effect of insulin-like growth factor-1 (1986) (69)
Growth hormone-releasing factor from ovine and caprine hypothalamus: isolation, sequence analysis and total synthesis. (1984) (69)
PHARMACOLOGY OF HYPOTHALAMIC REGULATORY PEPTIDES (1976) (68)
Immunoreactive and biologically active growth hormone-releasing factor in the rat placenta. (1985) (68)
S0MAT0STATIN-28tl-12)-LIKE IMMUNOREACTIVITY IN THE RAT (1982) (67)
Morphinomimetic activity of synthetic fragments of beta-lipotropin and analogs. (1976) (67)
Purification of peptides: an efficient procedure for the separation of peptides from amino acids and salt. (2009) (67)
Discovery of a series of nonpeptide small molecules that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. (2001) (65)
Pituitary secretion of growth hormone in response to opioid peptides and opiates is mediated through growth hormone-releasing factor. (1985) (65)
Isolation of an amino terminal extended form of basic fibroblast growth factor. (1986) (64)
Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. (2003) (64)
Isolation and characterization of rat pancreatic somatostatin. (1980) (63)
Nephroblastoma overexpressed gene (NOV) codes for a growth factor that induces protein tyrosine phosphorylation. (1999) (62)
Somatocrinin, the growth hormone releasing factor. (1984) (61)
Expression of insulin-like growth factor-binding protein-2 and -3 messenger ribonucleic acid in the porcine ovary: localization and physiological changes. (1992) (61)
Beta-endorphin-like immunoactivity in the plasma of heroin addicts and normal subjects (1980) (60)
Synthetic thyrotropin-releasing factor analogs. 3. Effect of replacement or modification of histidine residue on biological activity. (1972) (60)
Growth hormone releasing factors. (1985) (60)
Isolation and amino acid composition of two somatostatin-like peptides from ovine hypothalamus: somatostatin-28 and somatostatin-25. (1980) (60)
Inhibins and activins. (1988) (60)
The distribution and projection of γ-melanocyte stimulating hormone in the rat brain: An immunohistochemical analysis (1984) (60)
Rat atrial natriuretic factor suppresses proopiomelanocortin-derived peptides secretion from both anterior and intermediate lobe cells and growth hormone release from anterior lobe cells of rat pituitary in vitro. (1986) (59)
Invivo biological potency of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor (1983) (59)
Effect on an antagonistic analog of gonadotropin releasing hormone upon ovarian granulosa cell function. (1979) (59)
The effects of chronic central administration of corticotropin-releasing factor on food intake, body weight, and hypothalamic-pituitary-adrenocortical hormones. (1991) (58)
Ovarian intrabursal administration of insulin-like growth factor-binding protein inhibits follicle rupture in gonadotropin-treated immature female rats. (1991) (58)
Identification of a novel binding protein for insulin-like growth factors in adult rat serum. (1989) (58)
Development and validation of a radioimmunoassay for beta-endorphin-related peptides. (1981) (58)
Localization of the heparin binding site of follistatin (1992) (58)
Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. (1994) (58)
Foot-shock induced stress increases beta-endorphin levels in blood but not brain. (1977) (58)
Immunoreactive endorphins, lipotropins and corticotropins in a human nonpituitary tumor: evidence for a common precursor. (1978) (58)
Mechanism of the direct action of gonadotropin-releasing hormone and its antagonist on androgen biosynthesis by cultured rat testicular cells. (1983) (57)
Synthetic luteinizing hormone-releasing factor analogs. Series of short-chain amide LRF homologs converging to the amino terminus. (1973) (56)
HYPOTHALAMIC HYPOPITUITARISM FOLLOWING CRANIAL IRRADIATION FOR NASOPHARYNGEAL CARCINOMA (1986) (56)
Increased follistatin (activin-binding protein) gene expression in rat anterior pituitary tissue after ovariectomy may be mediated by pituitary activin. (1993) (55)
The heparin binding site of follistatin is involved in its interaction with activin. (1995) (54)
Localization of γ-melanocyte stimulating hormone (γMSH) immunoreactivity in rat brain and pituitary (1980) (54)
Immunological characterization of endorphins, adrenocorticotropin, and melanotropins in frog hypothalamus. (1983) (53)
Pituitary immunoreactive γ-melanotropins are glycosylated oligopeptides (1980) (53)
A noninvasive functional lesion of the hypothalamo-pituitary axis for the study of growth hormone-releasing factor. (1983) (52)
Plasma growth hormone response to growth hormone-releasing factor in acromegalic patients. (1984) (52)
Expression and regulation of insulin-like growth factor-binding protein-1, -2, -3, and -4 messenger ribonucleic acids in purified rat Leydig cells and their biological effects. (1993) (52)
β-Endorphin in obstetric analgesia☆ (1980) (52)
Solid phase synthesis of porcine α-endorphin and γ-endorphin, two hypothalamic-pituitary peptides with opiate activity (1977) (51)
In vitro release of growth hormone-releasing factor (GRF) from the hypothalamus: somatostatin inhibits GRF release (1991) (51)
THE ENDORPHINS, NOVEL PEPTIDES OF BRAIN AND HYPOPHYSIAL ORIGIN, WITH OPIATE‐LIKE ACTIVITY: BIOCHEMICAL AND BIOLOGIC STUDIES (1977) (51)
Extrapituitary actions of gonadotropin-releasing hormone: stimulation of insulin-like growth factor-binding protein-4 and atresia. (1994) (51)
Somatostatin-28 [1-12]-like peptides. (1985) (50)
Topographical study of the neurons containing hpGRF immunoreactivity in monkey hypothalamus (1983) (49)
Comparison of effects of adrenocorticotropin and Lys-gamma 3-melanocyte-stimulating hormone on steroidogenesis, adenosine 3',5'-monophosphate production, and phospholipid metabolism in rat adrenal fasciculata-reticularis cells in vitro. (1983) (49)
Demonstration by covalent cross-linking of a specific interaction between beta-endorphin and calmodulin. (1983) (49)
Characteristics of β-endorphin-induced behavioral activation and immobilization (1979) (49)
Human plasma free activin and inhibin levels during the menstrual cycle. (1993) (48)
Radioimmunoassay of follistatin: application for in vitro fertilization procedures. (1990) (46)
Regulation of testicular inhibin subunit messenger ribonucleic acid levels in vivo: effects of hypophysectomy and selective follicle-stimulating hormone replacement. (1989) (46)
A homodimer of the beta-subunits of inhibin A stimulates the secretion of pituitary follicle stimulating hormone. (1986) (46)
Orientation restrictions of the peptide hormone, thyrotropin-releasing factor, due to intramolecular hydrogen bonding. (1972) (45)
Growth Hormone-Releasing Factor: Chemistry and Physiology (1984) (45)
Inhibition of in vivo 3H-spiperone binding by the proposed antipsychotic des-try1-γ-endorphin (1979) (45)
Somatostatin-28, somatostatin-14 and somatostatin analogs: Effects on thermoregulation (1981) (44)
The satiety effect of growth hormone-releasing factor in rats (1985) (44)
Porcine ovarian granulosa cells secrete insulin-like growth factor-binding proteins-4 and -5 and express their messenger ribonucleic acids: regulation by follicle-stimulating hormone and insulin-like growth factor-1. (1994) (43)
Growth hormone (GH)-releasing factor does not regulate GH release or GH mRNA levels in GH3 cells. (1984) (43)
Applications of adenohypophyseal cell cultures to neuroendocrine studies. (1976) (43)
Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted at position-1. (1984) (43)
3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization. (2005) (43)
Examination of des-tyrosine1-gamma-endorphin activity at oH-spiroperidol binding sites in rat brain. (1979) (42)
Identification of a Nonpeptide Ligand That Releases Bioactive Insulin-like Growth Factor-I from Its Binding Protein Complex* (2001) (42)
The distribution of α-melanocyte stimulating hormone (α-MSH) in the central nervous system of the rat: An immunohistochemical study. II. Lower brain stem (1984) (42)
Brain corticotropin-releasing hormone increases arousal in stress (1991) (41)
A radioimmunoassay for γ-melanocyte stimulating hormone (1980) (41)
Insulin-induced hypoglycemia, l-dopa and arginine stimulate GH secretion through different mechanisms in man (1990) (41)
Radioimmunoassay for fibroblast growth factor (FGF): release by the bovine anterior pituitary in vitro (1985) (40)
Chemical, biological, and immunological characterization of mono- and diiodothyrotropin releasing factor. (1976) (40)
The absence of an age-related change in the pituitary response to growth hormone-releasing factor in rats. (1983) (40)
Immunocytochemical localization of prosomatostatin fragments in maturing and mature secretory granules of pancreatic and gastrointestinal D cells. (1983) (39)
Insulin-like growth factor binding protein-3 gene expression is restricted to involuting corpora lutea in rat ovaries. (1993) (39)
Effect of human growth hormone-releasing hormone on GH secretion in Cushing's syndrome and non-endocrine disease patients treated with glucocorticoids. (1988) (39)
Immunohistochemical evidence that brain enkephalins arise from a precursor similar to adrenal preproenkephalin (1983) (39)
Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency. (1988) (39)
Structure of the rat insulin-like growth factor binding protein-4 gene. (1993) (38)
Brain corticotropin-releasing factor acts as inhibitor of stress-induced gastric erosion in rats. (1990) (38)
[Molecular structure of the hypothalamic factor (LRF) of ovine origin monitoring the secretion of pituitary gonadotropic hormone of luteinization (LH)]. (1971) (38)
Insulin-like growth factor binding proteins show distinct patterns of expression in the rat uterus. (1994) (38)
A radioimmunoassay for γ1-melanotropin and evidence that the smallest pituitary γ-melanotropin is amidated at the COOH-terminus (1980) (38)
In vitro release of [5-methionine]enkephalin and [5-leucine]-enkephalin from the rat globus pallidus. (1978) (38)
Immunoreactive γ-Melanotropin in Rat Pituitary and Plasma: A Partial Characterization* (1982) (37)
Stage-specific cellular regulation of inhibin α-subunit mRNA expression in the rat seminiferous epithelium (1991) (37)
Antagonistic effect of somatostatin on corticotropin-releasing factor-induced anorexia in the rat. (1988) (37)
Neuropeptides derived from prosomatostatin that do not contain the somatostatin-14 sequence (1984) (37)
Solid-phase synthesis of two glycopeptides containing the amino acid sequence 5 to 9 of somatostatin. (1981) (37)
Corticotropin releasing factor activity of CRF 41 in normal man is potentiated by angiotensin II and vasopressin but not by desmopressin. (1988) (37)
Human pancreas GH-releasing factor analog restores high-amplitude GH pulses in CNS lesion-induced GH deficiency. (1983) (37)
Follistatin concentrations in follicular fluid of normal and polycystic ovaries. (1995) (36)
In vivo comparison of the follicle-stimulating hormone-suppressing activity of follistatin and inhibin in ovariectomized rats. (1991) (36)
Analogs of luteinizing hormone releasing factor (LRF) synthesis and biological activity of [(Nα-Me)Leu7]LRF and [D-Ala6,(Nα-Me)Leu7]LRF (1975) (36)
Novel Ovarian Regulatory Peptides: Inhibin, Activin, and Follistatin (1990) (36)
Differential control of activin, inhibin and follistatin proteins in cultured rat granulosa cells. (1993) (35)
Isolation and characterization of a γ1‐melanotropin‐like peptide from bovine neurointermediate pituitary (1981) (35)
Isolation and characterization of the bovine hypothalamic corticotropin-releasing factor. (1984) (35)
Gonadotropin and cAMP modulation of IGE binding protein production in ovarian granulosa cells. (1992) (35)
Profound Analgesic Effects of ??-Endorphin in Man (1981) (34)
Glycosylated human growth hormone (hGH): a novel 24 kDa hGH-N variant. (1996) (34)
Inhibition of gastric and pancreatic secretions by cerebroventricular injections of gastrin-releasing peptide and bombesin in rats (1982) (34)
Measurement of corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in human plasma by two-site enzyme-linked immunoabsorbant assay. (1996) (34)
Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902. (2007) (34)
Cloning of the rat insulin- like growth factor binding protein-5 gene and DNA sequence analysis of its promoter region. (1993) (33)
Gonadotropin-releasing activity of alpha-melanocyte-stimulating hormone in normal subjects and in subjects with hypothalamic-pituitary dysfunction. (1984) (33)
Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia (2005) (33)
Multiple stimulation of the adenohypophysis by combinations of hypothalamic releasing factors. (1984) (32)
Primary structures of three human pancreas peptides with growth hormone-releasing activity. (1983) (32)
Isolation and characterization of caprine corticotropin-releasing factor. (1984) (32)
Determinants of high-affinity binding and receptor activation in the N-terminus of CCL-19 (MIP-3 beta). (2004) (32)
Identification of beta-endorphin residues 14-25 as a region involved in the inhibition of calmodulin-stimulated phosphodiesterase activity. (1983) (32)
Increased sensitivity of adipose tissue to insulin after in vivo treatment of yellow Avy/A obese mice with amino-terminal peptides of human growth hormone. (1988) (31)
[Somatomedin inhibition of the growth hormone secretion stimulated by the hypothalamic factor somatocrinin or the synthetic peptide hpGRF]. (1982) (31)
Interleukin-1 induces insulin-like growth factor binding protein-3 gene expression and protein production by Leydig cells. (1995) (31)
Relative potencies of gonadotropin-releasing hormone agonists and antagonists on ovarian and pituitary functions. (1983) (31)
Circulating levels of follistatin from puberty to menopause. (1996) (31)
Synthesis of a glycotripeptide and a glycosomatostatin containing the 3-O-(2-acetamido-2-deoxy-beta-D-glucopyranosyl)-L-serine residue. (1981) (30)
Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly. (1986) (29)
The N-terminal domain of CCL21 reconstitutes high affinity binding, G protein activation, and chemotactic activity, to the C-terminal domain of CCL19. (2006) (29)
Insulin-like growth factor-binding protein-2: the effect of human chorionic gonadotropin on its gene regulation and protein secretion and its biological effects in rat Leydig cells. (1994) (29)
Immunosuppressive phenotype of corticotropin-releasing factor transgenic mice is reversed by adrenalectomy. (1997) (29)
Ovine corticotropin-releasing factor stimulates the concomitant secretion of corticotropin, β-lipotropin, β-endorphin and γ-melanotropin by the bovine adenohypophysis invitro (1982) (29)
Secretion pattern of pro-opiomelanocortin-derived peptides by a pituitary adenoma from a patient with Cushing's disease. (1981) (29)
Isolation and chemical characterization of somatostatin-28 from rat hypothalamus (1981) (29)
In vivo release of enkephalin from the globus pallidus (1981) (28)
Plasma growth hormone (GH) responses to single and repetitive subcutaneous administration of GH releasing factor (hpGRF-44) in normal and GH deficient children. (1985) (28)
Pituitary response to growth hormone-releasing factor in rats with functional or anatomical lesions of the central nervous system that inhibit endogenous growth hormone secretion (1984) (28)
Pituitary adenomas that caused Cushing's disease or Nelson's syndrome are not responsive to ovine corticotropin-releasing factor in vitro. (1983) (28)
Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands (2003) (27)
The influence of electro-acupuncture on naloxone-induced morphine withdrawal. II. Elevation of immunoassayable beta-endorphin activity in the brain but not the blood. (1979) (27)
Body Weight Regulation by Selective MC4 Receptor Agonists and Antagonists (2003) (26)
Expression of messenger RNA for insulin-like growth factors and insulin-like growth factor binding proteins by experimental breast cancer and normal breast tissue in vivo. (1992) (26)
Synthesis and conformations of hypothalamic hormone releasing factors: two QRF-analogues containing backbone N-methyl groups (1975) (26)
Physiological studies with somatocrinin, a growth hormone-releasing factor. (1985) (26)
Functional properties of covalent beta-endorphin peptide/calmodulin complexes. Chlorpromazine binding and phosphodiesterase activation. (1985) (26)
The in vivo metabolism of somatostatin 28: possible relationship between diminished metabolism and enhanced biological action. (1982) (26)
Interleukin-1 inhibits stress-induced gastric erosion in rats. (1991) (26)
Rat hypothalamic growth hormone-releasing factor: isolation, sequence analysis and total synthesis. (1984) (25)
Complementary DNA Sequences of Ovarian Follicular Fluid Inhibin Show Precursor Structure and Homology with Transforming Growth Factor β (1986) (25)
Regional distribution of rat growth hormone releasing factor-like immunoreactivity in rat hypothalamus. (1985) (25)
Expression of rat insulin-like growth factor binding protein-6 in the brain, spinal cord, and sensory ganglia. (2000) (25)
Attenuation of corticotropin releasing factor-induced hypotension in anesthetized rats with the CRF antagonist, α-helical CRF9–41; Comparison with effect on ACTH release (1992) (25)
Ontogeny of the response to growth hormone-releasing factor (1984) (25)
Initial structure-activity relationship studies of a novel series of pyrrolo[1,2-a]pyrimid-7-ones as GnRH receptor antagonists. (2002) (25)
Gonadocrinins: peptides in ovarian follicular fluid stimulating the secretion of pituitary gonadotropins. (1981) (25)
Site-specific mutagenesis of human follistatin. (1991) (24)
Corticotropin-releasing factor in the amacrine cells of the chicken retina (1984) (24)
Distribution of immunoreactive growth hormone releasing factor (1–44)NH2 in the tuberoinfundibular system of the rhesus monkey (1984) (24)
The antagonistic effect of corticotropin-releasing factor on pentobarbital in rats (1986) (23)
Immunoassayable beta-endorphin level in the plasma and CSF of heroin addicted and normal subjects before and after electroacupuncture. (1980) (23)
Processing of prosomatostatin. (1990) (23)
Stimulation of progesterone secretion by recombinant follistatin-288 in human granulosa cells. (1993) (23)
beta-Endorphin and deletion peptides. A correlation of opiate receptor affinity with helix potential. (1982) (23)
Characterization of the endorphins, novel hypothalamic and neurohypophysial peptides with opiate-like activity: evidence that they induce profound behavioral changes (1977) (23)
Interactions between growth hormone-releasing hormone and glucocorticoids in male rats (1989) (23)
Structural characterization of the rat insulin-like growth factor binding protein-6 gene. (1993) (23)
NMR Structural Characterization of a Minimal Peptide Antagonist Bound to the Extracellular Domain of the Corticotropin-releasing Factor1 Receptor* (2007) (22)
beta-endorphin: cellular localization, electrophysiological and behavioral effects. (1978) (22)
Effects of estrous cycle stage and pregnancy on follistatin gene expression and immunoreactivity in rat reproductive tissues: progesterone is implicated in regulating uterine gene expression. (1993) (22)
Control of Anterior Pituitary Hormone Secretion (1974) (22)
Structural and functional studies of insulin-like growth factor binding proteins in the ovary. (1993) (22)
‘γ-MSH’ fragments from ACTH-β-LPH precursor have an affinity for opiate receptors (1980) (21)
Effects of adrenergic blockers on corticotropin-releasing factor-induced behavioral changes in rats (1987) (21)
A 12-kilodalton N-glycosylated growth hormone-related peptide is present in human pituitary extracts. (1993) (21)
II. Atrial natriuretic factor (ANF) stimulates the release of α-MSH from frog neuro- intermediate lobes in vitro. Interaction with dopamine, GABA and neuropeptide Y. (1987) (21)
Radioimmunoassay for ?-endorphin (1978) (21)
Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted with a single D-amino acid. (1987) (21)
Immunoreactive growth hormone-releasing factor in human stalk median eminence. (1984) (20)
Molecular forms of the putative enkephalin precursor BAM-12P in bovine adrenal, pituitary, and hypothalamus. (1982) (20)
[Endorphins, hypothalamic and neurohypophysial peptides with morphinomimetic activity: isolation and molecular structure of alpha-endorphin]. (1976) (20)
Immunohistochemical evidence that growth hormone-releasing factor (GRF) neurons contain an amidated peptide derived from cleavage of the carboxyl-terminal end of the GRF precursor. (1986) (20)
α MELANOCYTE STIMULATING HORMONE INDUCES GONADOTROPIN RELEASE (1981) (20)
Profound analgesic effects of beta-endorphin in man. (1980) (20)
Growth Factor-Mediated Regulation of Aromatase Activity in Human Skin Fibroblasts (1991) (19)
Effect of dopamine, bombesin and cysteamine hydrochloride on plasma growth hormone response to synthetic growth hormone-releasing factor in rats. (1985) (19)
The somatostatin analog octreotide inhibits the secretion of growth hormone (GH)-releasing hormone, thyrotropin, and GH in man. (1989) (19)
Effects of neonatal administration of monosodium glutamate on plasma growth hormone (GH) response to GH-releasing factor in adult male and female rats (1986) (19)
Purification and characterization of luteinizing hormone-releasing hormone from codfish brain (1986) (19)
Blood pressure following microinjection of somatostatin related peptides into the rat nucleus tractus solitarii. (1985) (18)
Effects of feeding behavior of rats of a cryptic peptide from the C-terminal end on prepro-growth hormone-releasing factor. (1987) (18)
Synthesis and in vitro bioactivity of C-terminal deleted analogs of human growth hormone-releasing factor. (1984) (18)
SOMATOSTATIN‐28 INHIBITS LHRH‐STIMULATED GONADOTROPHIN SECRETION IN MAN (1982) (18)
Enkephalin-containing polypeptides are potent inhibitors of enkephalin degradation (1983) (18)
ISOLATION AND CHARACTERIZATION OF RAT HY POTH AL AM IC SOM ATOST AT IN-14 (1981) (18)
A Met-enkephalin-containing-peptide, BAM 22P, as a novel substrate for glandular kallikreins. (1983) (18)
Quinoline-carboxylic acids are potent inhibitors that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins. (2003) (18)
Direct sequence determination of ovine luteinizing hormone releasing factor by mass spectrometry. (1973) (17)
Analogues of luteinizing hormone releasing factor modified at positions 2, 6, and 10. (1976) (17)
Synthesis and characterization of IGF-II analogs: applications in the evaluation of IGF receptor function and IGF-independent actions of IGFBPs. (1993) (17)
In vitro study of frog (Rana ridibunda Pallas) interrenal function by use of a simplified perifusion system. VIII. Structure-activity relationship of synthetic ACTH fragments and gamma-MSH. (1986) (17)
Identification of rat S14 protein and comparison of its regulation with that of mRNA S14 employing synthetic peptide antisera. (1989) (17)
Immunofluorescence localization of thyroid hormone receptor protein /31 and variant a2 in selected tissues: Cerebellar Purkinje cells as a model for /81 receptor-mediated developmental effects of thyroid hormone in brain (17)
Human growth hormone releasing factor and somatostatin from two pancreatic tumors: isolation and characterization (1983) (17)
Hypothalamic regulation of growth hormone secretion during food deprivation in the rat. (1993) (17)
The regional distribution of γ 3-melanotropin-like peptides in bovine brain is correlated with adrenocorticotropin immunoreactivity but not with β-endorphin (1981) (17)
Purification and partial characterization of a mitogenic factor from bovine liver: structural homology with basic fibroblast growth factor (1986) (16)
Somatostatin-28(1-12)-like immunoreactivity in the rat. (1982) (16)
Identification of β-endorphin-(6–17) as the principal metabolite of des-tyrosine-γ-endorphin (DTγE) in vitro and assessment of its activity in neurotransmitter receptor binding assays (1982) (16)
Insulin-like growth factor binding protein measurement: sodium dodecyl sulfate-stable complexes with insulin-like growth factor in serum prevent accurate assessment of total binding protein content by ligand blotting. (1990) (16)
Somatocrinin receptor coupled with cAMP-dependent protein kinase on anterior pituitary granules. (1983) (15)
Amino-terminal extension analogs of methionine-enkephalin. (1978) (15)
Plasma growth hormone (GH) and somatomedin C response to continuous growth hormone-releasing factor (GRF) infusion in patients with GH deficiency. (1985) (15)
Radioimmunoassays for alpha-endorphin and beta-endorphin. (1977) (15)
The use of the corticotropin-releasing hormone test to monitor the recovery of patients with Cushing's disease or Cushing's syndrome due to an adrenal adenoma after adenomectomy. (1985) (15)
Ontogeny of pituitary responsiveness to corticotropin-releasing hormone in rat (1988) (15)
Studies on the structural prerequisites for the activation of the beta-endorphin receptor on the rat vas deferens. (1982) (15)
Synthetic analogs of growth hormone-releasing factor with antagonistic activity in vitro. (1990) (15)
Differential effects of haloperidol on the rat pituitary: decreased biosynthesis, processing and release of anterior lobe pro-opiomelanocortin. (1990) (14)
Immunocytochemical evidence for the presence of gamma 1-MSH-like immunoreactivity in pituitary corticotrophs and ACTH-producing tumours. (1983) (14)
Amino-terminal peptide of growth hormone enhances insulin action in normal rats. (1988) (14)
Microisolation of neuropeptides. (1983) (14)
Prosomatostatin-derived antrin is present in gastric D cells and in portal blood. (1989) (14)
Regulation of pulsatile gonadotropin secretion by estrogen, inhibin, and follistatin (activin-binding protein) in ovariectomized rats. (1992) (14)
Selective Impairment of Corticotropin-Releasing Factor1 (CRF1) Receptor-Mediated Function Using CRF Coupled to Saporin1. (2000) (14)
Atropisomeric property of 1-(2,6-difluorobenzyl)-3-[(2R)-amino-2-phenethyl]-5-(2-fluoro-3-methoxyphenyl)-6-methyluracil. (2005) (13)
[Preliminary observations on the mechanism of action of somatostatin, a hypothalamic factor inhibiting the secretion of growth hormone]. (1972) (13)
In Vitro and in Vivo Evidence that the C-Terminus of Preproenkephalin-A Circulates as an 8500-Dalton Molecule (1984) (13)
SOMATOSTATIN‐28 AND SOMATOSTATIN‐14 SUPPRESSION OF ARGININE‐, INSULIN‐, AND TRH‐STIMULATED GH AND PRL SECRETION IN MAN (1983) (13)
Isolation, primary structure, and synthesis of alpha-endorphin and gamma-endorphin, two peptides of hypothalamic-hypophysial origin with morphinomimetic activity. (1976) (13)
Stage dependent expression of inhibin alpha and beta-B subunits during the cycle of the rat seminiferous epithelium. (1989) (12)
A DIVERGENCE OF PLASMA GROWTH HORMONE RESPONSE BETWEEN GROWTH HORMONE‐RELEASING FACTOR AND INSULIN‐INDUCED HYPOGLYCAEMIA AMONG MIDDLE‐AGED HEALTHY MALE SUBJECTS (1986) (12)
Purification and properties of active atrial-natriuretic-peptide receptor (type C) from bovine lung. (1989) (12)
Concomitant release of FSH and LH induced by native and synthetic LRF. (1973) (12)
5 – Role of Insulin-like Growth Factors (IGF) and IGF-Binding Proteins in Folliculogenesis (1994) (12)
6,7-dihydroxyisoquinoline-3-carboxylic acids are potent inhibitors on the binding of insulin-like growth factor (IGF) to IGF-binding proteins: optimization of the 1-position benzoyl side chain. (2003) (12)
des-(1–13) Human β-endorphin interacts with calmodulin (1983) (11)
Restraint changes pentobarbital-induced sleeping time in rats: evidence that arousal is modulated by brain corticotropin-releasing hormone and opioid in stress (1994) (11)
Substituted NDP-MSH peptides paired with mutant melanocortin-4 receptors demonstrate the role of transmembrane 6 in receptor activation. (2007) (11)
In vivo biological potency of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor. (1983) (11)
Kappa-receptor specificity of [Met5]enkephalyl-Arg-Gly-Leu and [Met5]enkephalyl-Arg-Gly-Leu-Lys. (1983) (11)
Plasma growth hormone responses to repetitive administrations of growth hormone releasing factor in patients with pituitary dwarfism. (1984) (11)
Peptides: Strategies for Antibody Production and Radioimmunoassays (1987) (11)
Selective impairment of corticotropin-releasing factor1 (CRF1) receptor-mediated function using CRF coupled to saporin. (2000) (11)
Effects of peptides of pituitary origin on the formation of C21 steroid by fetal calf adrenal cells in culture. (1977) (11)
Interaction of tritiated β-endorphin with rat brain membranes (1981) (10)
Effect of sodium ion on atrial natriuretic factor release from rat hypothalamic fragments. (1988) (9)
Plasma GH response to hpGRF-44 in normal children of short stature and patients with GH deficiency. (1984) (9)
Synthesis and biological activity of glycosylated analogs of somatostatin. (1979) (8)
beta-Endorphin in obstetric analgesia. (1980) (8)
Growth hormone-releasing factor: a new chapter in neuroendocrinology. (1986) (8)
Preparation of tritium labeled beta-endorphin suitable for studying brain receptor interactions. (1981) (7)
The inter- and intra-subject variabilities of plasma GH response to human growth hormone-releasing hormone (1-44) NH2 in men. (1985) (7)
Probing the biologically and immunologically active conformation of beta-endorphin: studies on C-terminal deletion analogs. (1980) (7)
Chemistry of hypothalamic releasing factors. (1973) (7)
Atrial natriuretic factor (ANF) stimulates the release of alpha-MSH from frog neurointermediate lobes in vitro. Interaction with dopamine, GABA and neuropeptide Y. (1987) (6)
Somatostatin-28 inhibits thyroid-stimulating hormone release in man. (1982) (6)
On the biological activities of the synthetic tetrapeptide pyroglutamyl-tyrosyl-arginyl-tryptophanyl-amide. (1972) (6)
Inhibins and activins a (1988) (6)
Characterization of [125I-Tyr0]-corticotropin releasing factor (CRF) binding to the CRF binding protein using a scintillation proximity assay (1998) (6)
Radioimmunoassay of inhibin based on synthetic human inhibin alpha-chain peptide. (1991) (6)
Conformation of β-endorphin analogues in cerebroside sulfate solution (1981) (6)
Synergistical effects of ovine corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) on the release of pro-opiomelanocortin (POMC) related peptides by pituitary adenoma of a patient with Nelson's syndrome in vitro. (1984) (6)
Polypeptides antagonists of the hypothalamic luteinizing hormone releasing factor. (1971) (6)
Gonadostatins and Gonadocrinin: Peptides from the Gonads Regulating the Secretion of Gonadotropins (1981) (6)
Regulation of IGFBP-4 and -5 expression in rat granulosa cells. (1993) (5)
Effect ofα-methyl-p-tyrosine and an antiserum to rat growth hormone (GH)-releasing factor (GRF) on plasma GH secretory profile during a continuous infusion of human GRF in rats (1988) (5)
Isolation and characterization of hypothalamic peptide hormones. (1976) (5)
Synthesis and properties of some peptides related to the bicyclic β-turn dipeptide (BTD) (1988) (5)
Plasma growth hormone secretion during constant growth hormone-releasing factor infusion. (1984) (5)
Isolation and characterization of rat hypothalamic somatostatin-14. (1981) (5)
Contribution of the amino terminal tyrosine to the interaction of γ-endorphin with opiate receptors (1982) (5)
Secretion of N-terminal pro-opiomelanocortin-derived peptides in response to acute haemorrhagic stress in conscious sheep. (1985) (5)
Analogs of luteinizing hormone releasing factor (LRF). Synthesis and biological activity of ((Nalpha-Me)Leu-7)LRF and (D-Ala-6,(Nalpha-Me)Leu-7)LRF. (1975) (5)
Relative potencies of human, rat, bovine/caprine, porcine and ovine hypothalamic growth hormone-releasing factors to release growth hormone by the rat anterior pituitary in vitro. (1986) (5)
Atrial natriuretic factor increases cyclic GMP and cyclic AMP levels in a directly photosensitive pineal organ (1990) (4)
hpGRF-44-NH2, lot no. 92-81-5G-41-47, is (human) growth hormone-releasing factor containing no trace of (ovine) corticotropin-releasing factor. (1986) (4)
Plasma growth hormone response to human growth hormone releasing factor in rats administered with chlorpromazine and antiserum against somatostatin. Effects of hypo- and hyperthyroidism. (1985) (4)
Polypeptide antagonists of the hypothalamic luteinizing hormone releasing factors. (1973) (4)
Inhibition of pancreatic hormone secretion by somatostatin-28 and somatostatin-14 in man. (1983) (4)
Immunoreactive gamma-melanotropin in rat pituitary and plasma: a partial characterization. (1982) (4)
ABNORMAL BRAIN OPIATE MECHANISMS IN SCHIZOPHRENIA (1980) (4)
Effect of hypthalamic ventromedial lesions on plasma growth hormone response to growth hormone-releasing factor in rats (1985) (4)
Myelin basic protein present in the acid extracts of rat hypothalami releases insulin and glucagon from isolated rat pancreatic islets. (1988) (4)
Plasma growth hormone and somatomedin-C responses to continuous growth hormone-releasing factor infusion in normal adult men. (1985) (4)
Therapeutic agents produced by genetic engineering: Quo vadis? The example of growth hormone and its releasing factor. Satellite symposium. Toulouse-Labège, May 29-30, 1985. (1986) (3)
Lack of effect of native or synthetic LRF on secretion of prolactin in vitro. (1973) (3)
Arginine hydrochloride stimulation of serum potassium and aldosterone is enhanced by somatostatin-28. (1984) (3)
Growth hormone-releasing factor analogs with potent antagonist activity (1988) (3)
Plasma beta-endorphin levels during obstetrical analgesia with synthetic beta-endorphin. (1986) (3)
Possible role of opiate receptors and des-tyrosine1-gamma-endorphin in schizophrenia. (1980) (3)
Radioimmunoassay of human prolactin based on a 13 amino acid synthetic analog of the amino terminus. (1983) (3)
Desensitization of rat pituitary somatotrophs to growth hormone-releasing factor occurs in vitro. (1987) (3)
Corticotropin-releasing factor reverses the effect of pentobarbital through a beta-noradrenergic mechanism in rats. (1988) (3)
Alpha-melanocyte stimulating hormone induces gonadotropin release. (1981) (3)
Localization of gamma-melanocyte stimulating hormone (gamma MSH) immunoreactivity in rat brain and pituitary. (1980) (3)
[Solid-phase total synthesis of a tetradecapeptide having the chemical and biological properties of somatostatine]. (1973) (3)
Phosphorylation of basic fibroblast growth factor by purified protein kinase C and the identification of a cryptic site of phosphorylation. (1991) (3)
beta-Endorphin secretion of arginine vasopressin in vivo. (1977) (3)
Inhibins and activins. Structures and radioimmunoassays. (1988) (2)
Immunocytochemical demonstration of GAP-like immunoreactive neuronal elements in the human hypothalamus and pituitary (2006) (2)
Interaction of α-N-acetyl-β-endorphin and calmodulin (1988) (2)
Identification of beta-endorphin-6(16-17) as the principal metabolite of des-tyrosin-gamma-endorphin (DTgammaE) in vitro and assessment of its activity in neurotransmitter receptor binding assays. (1982) (2)
Isolation and partial characterization of follistatin : A single-chain Mr 35 , 000 monomeric protein that inhibits the release of follicle-stimulating hormone ( ovary / pituitary / luteinizing hormone / gonadotropins / porcine foilicular fluid ) (1)
Study of human growth hormone structure with a radioimmunoassay specific for the fifteen amino acid fragment comprising hGH (32–46) (1983) (1)
A radioimmunoassay for gamma 1-melanotropin and evidence that the smallest pituitary gamma-melanotropin is amidated at the COOH-terminus. (1980) (1)
Ovine corticotropin-releasing factor stimulates the concomitant secretion of corticotropin, beta-lipotropin, beta-endorphin and gamma-melanotropin by the bovine adenohypophysis in vitro. (1982) (1)
Solid phase synthesis of human growth hormone-releasing factor analogs containing a bicyclic beta-turn dipeptide. (1991) (1)
Intrathecal Use of Beta-Endorphin as a Powerful Analgetic Agent in Man (1982) (1)
Pituitary immunoreactive gamma-melanotropins are glycosylated oligopeptides. (1980) (1)
ANALOGUES OF LUTEINIZING HORMONE RELEASING FACTOR MODIFIED AT POSITIONS 2, 6, AND 10 (1976) (1)
[High biological activity of the synthetic counterparts of hypothalamic somatostatin-28 and somatostatin-25]. (1980) (1)
'gamma-MSH' fragments from ACTH-beta-LPH precursor have an affinity for opiate receptors. (1980) (1)
Synthesis and biological activity of four gamma-melanotropin peptides derived from the cryuptic region of the adrenocorticotropin/beta-lipotropin precursor. (1979) (1)
Insulin-like growth factor-1 (IGF-1) stimulates the IGF binding protein system in rat theca interstitial cells (1995) (1)
A radioimmunoassay for human pro-luteinizing hormone-releasing factor [pro-LRF(14-69)OH]. (1987) (1)
The Endocrine Society Seventy-First Annual Meeting June 21-24, 1989, Seattle, Washington (1989) (0)
APPUCATIONSINTHEEVALUATIONOFIGFRECEPTORFUNCl10N AND IGF-INDEPENDENT ACl10NS OFIGFBPS (1994) (0)
Tissue specific and cyclic expression of insulin-like growth factor binding proteins-1,-2,-3,-4,-5,-6 in the rat oviduct (1995) (0)
Erratum (1975) (0)
A United States Patent ( 19 ) 11 Patent Number : 5 , 492 , 894 (2017) (0)
Purification of gonadostatin from bovine seminal plasma (BSP). (1982) (0)
Inhibition of in vivo 3H-spiperone binding by the proposed antipsychotic Des-Tyr1-gamma-endorphin. (1979) (0)
Conformation of beta-endorphin analogues in cerebroside sulfate solution. (1981) (0)
Bound Structure of CRF1 Extracellular Domain Antagonist (2006) (0)
Comparison of somatostatin14 and somatostatin28 binding sites in rat brain and adenohypophysis (1984) (0)
α- and β-Heparin Binding Growth Factors: Chemistry and Biology of Acidic and Basic Fibroblast Growth Factors (1987) (0)
Process for producing a peptide having an impact on human and other mammalian hypofysekirtelfunktion (1983) (0)
Abstracts of Selected Free Communications (1986) (0)
Antagonists of the fibroblast growth factor. (1987) (0)
Regional dissociation of f ,-endorphin and enkephalin contents in rat brain and pituitary ( opiates / radioimmunoassay / neurotransmitter / adrenalectomy and hypophysectomy / myelin basic protein ) (0)
Structural Characterization of a Minimal Peptide Antagonist Bound to the Extracellular Domain of the Corticotropin-Releasing Factor 1 ( CRF 1 ) Receptor (2006) (0)
des-(1-13) human beta-endorphin interacts with calmodulin. (1983) (0)
The regional distribution of gamma 3-melanotropin-like peptides in bovine brain is correlated with adrenocorticotropin immunoreactivity but not with beta-endorphin. (1981) (0)
Growth hormone releasing factor , somatocrinin , releases pituitary growth hormone in vitro ( hypothalamus / pancreas / tumor / somatostatin / perifusion (0)
Isolation and characterization of growth factors from porcine ovarian follicular fluid. (1991) (0)
Solid phase synthesis of porcine alpha-endorphin and gamma-endorphin, two hypothalamic-pituitary peptides with opiate activity. (1977) (0)
Interaction of tritiated beta-endorphin with rat brain membranes. (1981) (0)
SELECTIVITY OF OPIATE AND OPIOID PEPTIDE INTERACTION WITH CEREBROSIDE SULFATE (1981) (0)
Effects of forskolin and cholera toxin on cyclic AMP release in a neurotensin-secreting rat C-cell line. (1984) (0)
[Roles of cyclic AMP and calcium in the mechanism of the release of growth hormone by somatocrinin]. (1984) (0)
Radioimmunoassay for gamma-endorphin. (1978) (0)
Biological Activity and Mechanisms of Action of Somatocrinin, Growth Hormone Releasing Factor, on the Release of Growth Hormone in Vitro and its Antagonism by Somatostatin (1984) (0)
SYNTHETIC LUTEINIZING HORMONE RELEASING FACTOR ANALOGS, SERIES OF SHORT-CHAIN AMIDE LRF HOMOLOGS CONVERGING TO THE AMINO TERMINUS (1973) (0)
Molecular forms of the putative enkephalin precursor BAM-12 P in bovine adrenal , pituitary , and hypothalamus ( adrenal medulla / radioimmunoassay / opioid peptide / proenkephalin ) (0)
Follistatin and method thereof for cleaning. (1988) (0)
Inhibin and its cleaning. (1986) (0)
A radioimmunoassay for gamma-melanocyte stimulating hormone. (1980) (0)
Analogifremgangsmaade for the preparation of pGRF pGRF analogs or peptides, pharmaceutically acceptable addition salts thereof as well as intermediate for use in the method (1983) (0)
Solid phase synthesis of human growth hormone-releasing factor analogs containing a bicyclic β-turn dipeptide (2009) (0)
B-Lipotropin as a prohormone for the morphinomimetic peptides endorphins and enkephalins ( lipotropin / morphine / brain / endogenous ligand / pituitary ) (0)
Plasma GH and somatomedin C responses to single and repeated administrations of human growth hormone releasing factor (hGRF). (1985) (0)
[Increase by somatocrinin of a cyclic AMP-dependent protein kinase activity in adenohypophyseal, secretory granules in the hog]. (1983) (0)
4956455 Bovine fibroblast growth factor (1990) (0)
Initial Structure—Activity Relationship Studies of a Novel Series of Pyrrolo[1,2-a]pyrimid-7-ones as GnRH Receptor Antagonists. (2002) (0)
The potential use of LRF and its analogues for regulating fertility. (1981) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nicholas C. Ling?

Nicholas C. Ling is affiliated with the following schools:

Nicholas C. Ling's Academic­Influence.com Rankings

Nicholas C. Ling's Degrees

Why Is Nicholas C. Ling Influential?

Nicholas C. Ling's Published Works

Published Works

What Schools Are Affiliated With Nicholas C. Ling?

Nicholas C. Ling's AcademicInfluence.com Rankings